Eurofins unit partners with Gingko on COVID-19 testing

By LabPulse.com staff writers

December 13, 2021 -- Eurofins Scientific subsidiary Clinical Enterprise and Ginkgo Bioworks have formed a partnership to support a federally funded COVID-19 polymerase chain reaction (PCR) testing program in schools, community organizations, and underserved populations.

The Operation Expanded Testing program is funded by the U.S. Department of Health and Human Services and the Department of Defense. The program aims to provide COVID-19 PCR testing to K-12 public and private schools, historically Black colleges and universities, daycare centers, community organizations, congregate settings, correctional facilities, and underserved communities.

Clinical Enterprise and Ginkgo will provide these organizations with fast and reliable products to help detect asymptomatic infections to reduce transmission, prevent outbreaks, and protect vulnerable populations, as well as expand testing to more sites and organizations, the companies said.

Eurofins launches assay to detect omicron variant of COVID
Eurofins Technologies has launched a multiplex reverse transcription polymerase chain reaction assay that can detect the omicron variant of COVID-19.
Eurofins debuts 2 combined tests for COVID/influenza, RSV
Eurofins Technologies has launched two new reverse transcription polymerase chain reaction tests for the simultaneous detection of SARS-CoV-2, influenza...
Eurofins lands $30M COVID diagnostic testing contract
Eurofins Genomics has won a $30 million contract with the U.S. Department of Air Force and the U.S. Department of Health and Human Services to build...
Ginkgo Bioworks will go public in SPAC deal worth over $1.6B
Cell programming company Ginkgo Bioworks will go public after it finalizes a $1.6 billion deal with Soaring Eagle Acquisition, a special purpose acquisition...
Everlywell, Gingko Bioworks to distribute COVID-19 antigen test
Everlywell has signed an agreement with Ginkgo Bioworks to distribute Access Bio's CareStart COVID-19 antigen test to workplaces, clinics, schools, government...
Gingko raises $70M, plans NGS deployment against coronavirus
Cell programming company Ginkgo Bioworks has announced $70 million in funding to use its technology to address the ongoing COVID-19 pandemic.

Copyright © 2021 LabPulse.com

Last Updated np 12/13/2021 5:37:31 PM



Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current